Cediranib
Ovarian Mixed Germ Cell Tumor
City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Ovarian Mixed Germ Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab National Cancer Institute (NCI) | Phase 1 | CC |
Evomela City of Hope Medical Center | Phase 1 | CC |
FILGRASTIM City of Hope Medical Center | Phase 1 | CC |
Fludarabine City of Hope Medical Center | Phase 1 | CC |
Romidepsin City of Hope Medical Center | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →